Dementia-Related 
Behavior Management
By Mark D. Coggins,  PharmD, CGP, FASCPAging WellVol. 5 No. 1 P. 32
Dementia describes a group of symptoms resulting in a  gradual and progressive decline in memory, thinking, and reasoning abilities.  While most dementias are progressive with no cure, approximately 20% are  reversible. Healthcare professionals should closely evaluate patients with  cognitive decline for possible underlying treatable conditions. 
Medication-induced dementia is the most common cause of reversible  dementia. Elders are especially vulnerable due to concomitant illnesses,  reduced renal and liver function, and the simultaneous use of multiple  medications.1 
Other common reversible causes include depression,  infection, high fever, vitamin deficiencies, poor nutrition, hypercalcemia,  brain tumors, thyroid disorders, and hypoxia due to lung and heart diseases. 
Alzheimer’s disease (AD) is the most common type of  irreversible dementia. Other irreversible types include vascular or  multi-infarct dementia, dementia with Lewy bodies (DLB), frontotemporal  dementias (Pick’s disease), and Parkinson’s dementia (PD). Autopsy studies have  shown that most dementia patients had brain abnormalities consistent with more  than one dementia type.  
Dementia Behaviors              In addition to progressive cognitive loss, almost all AD  patients develop personality and significant behavioral changes. Mood disorders  such as depression; nonpsychotic behaviors such as restlessness, wandering, and  aggression; or psychotic symptoms, including hallucinations and delusions,  often occur with severe disruptive behaviors, leading to 50% of nursing home  admissions, according to the American Academy of Family Physicians. 
Healthcare professionals should consider behaviors as a  means of patient communication as AD patients lose their ability to adequately  make their needs known. Agitation may be a result of underlying precipitating  causes such as hunger, thirst, pain, or infection. Be aware that medication  changes or poor hearing can increase confusion. Vision issues can contribute to  visual hallucinations or increase a patient’s feeling of vulnerability or fear. 
The failure to identify causes of these behaviors may leave  a patient in distress and often results in the unnecessary use of behavior  management medications. These may do little more than cause sedation and can  lead to further cognitive decline, reduced patient activity, worsening  incontinence, and falls, and make it more difficult for caregivers to provide  assistance.   
In cases where the behavior or psychiatric symptoms are  severe, distressing, or may lead to harm, it may be necessary to prescribe  medications.
Antipsychotic Use and  Associated Risks              Antipsychotic use in dementia patients continues to be  widespread despite clear and substantial risks to patient health.  
All antipsychotic medications include FDA black box warnings  due to the increased risk of death when used in dementia-related psychosis.  Additional concerns include negative metabolic effects, weight gain, type 2 diabetes,  dyslipidemia, and increased risk of stroke. Antipsychotics are also linked to a  worsening decline in cognition consistent with one year’s deterioration  compared with placebo.
Antipsychotics in AD patients should be reserved for  behaviors that are harmful or when distressing psychotic features exist. They  should be given short-term and at the lowest possible dose with frequent  evaluation for discontinuation, according to the 2001 report “Psychotropic Drug  Use in Nursing Homes” by the Office of Inspector General. 
The widespread use of atypical antipsychotics despite the  risks highlights the need for alternative behavior management medications and  strategies.  
Medication management in dementia patients can be complex.  Unfortunately, no silver bullet exists for prescribers to call on to address  dementia-related behaviors. Successful behavior management most often involves  a combination of nonpharmacological approaches tailored to meet a patient’s  needs in addition to one or more of the currently available medications, which  often have limited supporting evidence in their effectiveness on  behaviors.   
Pain Treatment Can  Influence Behaviors              Pain can diminish cognitive function, reduce patients’  ability to perform activities of daily living, adversely affect mood, and  reduce quality of life.  
In a 2010 study conducted at a Golden LivingCenter in  Hendersonville, North Carolina,2 researchers found that increased pain  management focus in nursing home patients with dementia helped reduce episodic  behaviors. A certified geriatric pharmacist (CGP) provided education on pain  assessment and treatment options to all nursing home staff and direct care  assistants.  
The CGP evaluated medical records of patients with such  behaviors to determine whether common conditions known to cause pain, such as  osteoarthritis, wounds, and neuropathy, were being treated. Recommendations  based on the American Medical Directors Association pain management guidelines,  including acetaminophen and other medications, were discussed with each  patient’s physician, and appropriate medication changes were implemented.  Following the treatment modification, the patients’ behaviors were tracked and  were noted as significantly reduced, and nurses and nursing assistants noted  that patients had become less resistant to care.   
Additional follow-up discussions occurred between the  nursing home interdisciplinary team and the CGP. As patient behaviors improved,  the interdisciplinary team worked with prescribers to significantly reduce the  number of antipsychotic, anxiolytic medications (benzodiazepines) and  sedative/hypnotics being taken by these patients.2  
Nursing home patients in Norway and England with moderate to  severe dementia experiencing agitated behaviors had acetaminophen added to their  existing pain orders or, if acetaminophen was already ordered, low doses of  morphine, or they were given antiepileptic medications for neuropathic pain.  Patients receiving more aggressive pain management had a significant reduction  in undesirable behaviors. Following eight weeks of therapy, pain treatment  added to the intervention group was gradually reduced. Follow-up four weeks  later showed the recurrence of the behavior symptoms and further demonstrated  the effectiveness of pain management in reducing negative behaviors.3 
Cognitive Enhancers              Medications commonly given to slow the progression of  cognitive loss in dementia have shown modest benefit in controlling behaviors.
In several studies, acetylcholinesterase inhibitors  (AchEIs), donepezil (Aricept), rivastigmine (Exelon), and galantamine  (Razadyme) demonstrated some success in reducing dementia behavioral symptoms,  including apathy, anxiety, delusions, and hallucinations. These medications  appear to be effective in treating psychotic symptoms in patients with DLBT and  PD. 
Memantine (Namenda), an NMDA receptor antagonist used alone  and with AchEIs, has shown moderate improvements in behavioral symptoms,  including agitation, aggression, irritability, lability, and delusions.  Additional benefits have been seen when using memantine together with  AchEIs.4  
Antidepressants              Researchers have reviewed the evidence for the effectiveness  and safety of antidepressants for dementia-related agitation and psychosis.  While larger well-controlled studies are needed, many existing studies have  provided hope that antidepressants, especially those known as selective  serotonin reuptake inhibitors (SSRIs), have safe and tolerable side effect  profiles and can be effectively used to help dementia-related behaviors in some  patients. 
Most of the studies involved SSRIs such as citalopram  (Celexa) or sertraline (Zoloft). Improvements in depression, emotionality,  anxiety, agitation, and social interaction have been seen when comparing  citalopram with placebo. 
In a study at the University of Pittsburgh Medical Center  conducted with patients hospitalized with psychiatric disturbances related to  dementia, patients receiving citalopram experienced similar results, or a 32%  reduction in relieving hallucinations, delusions, and suspicious thoughts while  those in the atypical antipsychotic risperidone (Risperadal) group had a 35%  reduction. However, the patients receiving citalopram experienced a 4%  reduction in side effects compared with a 19% increase in side effects in patients  receiving risperidone.5  
Many antidepressants have been shown to have favorable  effects on anxiety, sleep disturbance, and agitated behaviors. Practical  suggestions on ways to implement the use of antidepressants for behaviors may  include selecting an agent based on the known beneficial effects and the  specific behavioral symptoms exhibited. 
SSRIs such as escitalopram (Lexapro) and sertraline have  indications to treat anxiety. Because anxiety and agitation are often closely  related, a reasonable selection of one of these antidepressants may be made for  those dementia patients exhibiting signs and symptoms of depression with  anxious agitated behaviors.  
Prescribers may choose to start antidepressant medications  such as SSRIs while slowly reducing or eliminating the use of higher risk  medications, such as antipsychotics and benzodiazepines that are often used for  anxiety. This can have further benefits for the patient since these medications  are known to increase confusion and fall risk.
              Depression is known to affect sleep in many patients with  and without dementia. Patients receive benzodiazepines or hypnotic medications  such as zolpidem (Ambien) for sleep, which has been linked to early morning  falls. Physicians may choose to utilize the antidepressant mirtazepine  (Remeron) at a dose of 30 mg for which there are studies showing improved sleep  continuity long term.   
Patients with dementia and diabetic neuropathy who exhibit  undesirable behaviors may be experiencing pain. Consideration for this type of  patient may be given to duloxetine (Cymbalta), an antidepressant known to help  neuropathic pain and depression. 
Pharmacological choices with FDA-approved indications and  clear evidence in targeting behaviors in dementia are limited. However,  improved nonpharmacological interventions, in addition to focused patient  individualized prescribing targeting common underlying causes of behaviors seen  in dementia patients, may allow for improved behavior symptom control with less  risk than is currently seen today utilizing atypical antipsychotic  medications.  
— Mark D. Coggins,  PharmD, CGP, FASCP, is the national director of clinical pharmacy services for  more than 300 skilled nursing homes operated by Golden Living. He was  recognized by the Commission for Certification in Geriatric Pharmacy with the  2010 Excellence in Geriatric Pharmacy Practice Award.
 
References              1. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and  preventability of adverse drug events among older persons in the ambulatory  setting. 
JAMA. 2003;289(9);1107-1116.
2. Coggins M, Evans MP, Bruce C. Effect of an  interdisciplinary team approach to psychotropic drug reduction and elimination  on quality measures and other clinical outcomes in skilled nursing facilities  (SNFs): the Medication Evaluation Trial (MET trial). 
JAMDA. 2010;11(3):B9.
3. Husebo BS, Ballard C, Sandvik R, Bjarte Nilsen O,  Aarsland D. Efficacy in treating pain to reduce behavioural disturbances in  residents of nursing homes with dementia: cluster randomized clinical trial. 
BMJ.  2011;343:d4065.
4. Gauthier S, Wirth Y, Möbius HJ. Effects of memantine on  behavioural symptoms in Alzheimer’s disease patients: an analysis of the  neuropsychiatric inventory (NPI) data of two randomized, controlled studies. 
Int J  Geriatr Psychiatry. 2005;20(5):459-464.
5. Pollock BG, Mulsant BH, Rosen J, et al. A double-blind  comparison of citalopram and risperidone for the treatment of behavioral and  psychotic symptoms associated with dementia. 
Am J Geriatr Psychiatry.  2007;15(11):942-952.